CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Furthering cell therapy ambition across oncology and autoimmune diseases
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Subscribe To Our Newsletter & Stay Updated
